Together, these findings uncover an epigenetic regulatory axis—HDAC3–NRF2–GPX4—that governs ferroptosis in CRC and propose HDAC3 as a potential therapeutic target for sensitizing tumors to ferroptosis-inducing treatments. Here, HDAC3 is linked to colorectal carcinoma.